{"url":"https://whatshealthyandwhy.com/lipoprotein-a/cardiovascular-risk","path":"/lipoprotein-a/cardiovascular-risk","alternates":{"json":"https://whatshealthyandwhy.com/api/articles/lipoprotein-a/cardiovascular-risk.json","markdown":"https://whatshealthyandwhy.com/lipoprotein-a/cardiovascular-risk.md"},"topic":{"slug":"lipoprotein-a","name":"Lipoprotein A","url":"https://whatshealthyandwhy.com/lipoprotein-a"},"slug":"cardiovascular-risk","order":1,"title":"Lipoprotein(a) and Cardiovascular Risk","question":"Does high lipoprotein(a) raise heart attack risk, and should I get tested?","answer":"High lipoprotein(a) probably raises the risk of heart attack, stroke and aortic valve disease, and one blood test shows your level.","description":"Genetic blood particle that predicts heart attack, stroke, and aortic stenosis independently of LDL cholesterol — what the evidence says about diet, niacin, and the new RNA-based therapies on the horizon","confidence":4,"confidenceNote":"Meta-analysis of 36 prospective studies (126,634 people) plus Mendelian randomisation agree; no outcome trial yet shows lowering Lp(a) prevents events.","evidenceSummary":{"rctCount":3,"observationalCount":1,"metaAnalysisCount":3,"totalParticipants":"300,000+","replicated":true,"newestStudyYear":2020},"category":{"categoryTitle":"Your Body","categorySlug":"your-body","subcategoryName":"Body Systems","subcategorySlug":"systems","url":"https://whatshealthyandwhy.com/explore/your-body/systems"},"actions":["Ask for a one-time Lp(a) blood test, an add-on to a standard lipid panel; societies recommend testing once in adulthood [1].","If it is high, push every other risk factor down: lower LDL, control blood pressure, do not smoke and exercise regularly.","Prefer a Mediterranean-style pattern over strict low-fat, high-carbohydrate eating, which raised Lp(a) about 12% in a 63-person feeding trial [8]."],"cautions":["Niacin lowers Lp(a) about 23% but did not reduce heart events and increased side effects; it is not recommended for this [7].","Newer RNA-based drugs lower Lp(a) sharply but are not yet proven to prevent heart attacks; outcome results are expected 2026–2027 [4].","Discuss your result with a cardiologist or lipidologist, especially with a family history of early heart attack or stroke."],"simpleText":"Lipoprotein(a) — usually written Lp(a) and pronounced \"L-P-little-a\" — is a cholesterol-carrying particle in your blood that's been called \"the cholesterol you've never heard of.\" Roughly one in five people inherit elevated Lp(a) from their parents, and it independently raises the risk of heart attack, stroke, and a heart-valve condition called aortic stenosis — even when LDL cholesterol looks fine. [1] [2] [3] Most people have never had it tested, despite expert societies now recommending a once-in-a-lifetime check. The good news: you can ask for a single inexpensive blood test, and knowing your number changes how aggressively you treat the things you can modify, like LDL, blood pressure, smoking, and inflammation.","mediumText":"What Lp(a) Actually Is and Why It Matters\n\nLp(a) is essentially an LDL (\"bad cholesterol\") particle with an extra protein bolted on — apolipoprotein(a), or apo(a) — that resembles a clot-related molecule called plasminogen. This unusual structure gives Lp(a) a triple personality: it deposits cholesterol in artery walls like LDL, it carries oxidised phospholipids that drive inflammation, and the apo(a) tail interferes with normal clot breakdown. [1] The combination is why Lp(a) is uniquely good at promoting both atherosclerosis (artery plaque) and thrombosis (clot formation), and why it causes calcific aortic valve disease — the gradual stiffening of the heart's main outflow valve — in a way ordinary LDL does not. [5] [6]\n\nYour Lp(a) level is set primarily by the LPA gene you inherited and remains remarkably stable across your lifetime — diet, exercise, and weight loss barely move it. [1] About 20–25% of people worldwide have levels high enough to meaningfully raise cardiovascular risk (typically defined as ≥50 mg/dL or ≥125 nmol/L). Levels are higher on average in people of African ancestry and lower on average in East Asian populations, but elevated Lp(a) occurs in every group.\n\nWho Should Get Tested\n\nMajor lipid societies — including the European Atherosclerosis Society and the National Lipid Association — now recommend testing Lp(a) at least once in adulthood, especially in:\n- Anyone with a personal or family history of premature heart attack or stroke (before age 55 in men, 65 in women)\n- People with familial hypercholesterolemia or unexplained high LDL\n- Anyone with calcific aortic valve disease, regardless of age\n- Family members of someone with known elevated Lp(a)\n\nThe test is a simple add-on to a standard lipid panel. Because Lp(a) barely changes over time, a single result is usually enough.\n\nInterpreting Your Number\n\nLp(a) is reported in either mg/dL (mass) or nmol/L (particle number) — the two units don't convert cleanly, but both are commonly used:\n- Optimal: <30 mg/dL (or <75 nmol/L)\n- Borderline: 30–50 mg/dL (or 75–125 nmol/L)\n- High risk: ≥50 mg/dL (or ≥125 nmol/L)\n- Very high risk: ≥180 mg/dL (or ≥430 nmol/L) — comparable to having heterozygous familial hypercholesterolemia\n\nRisk rises continuously with concentration; there's no clean cliff edge. [2]\n\nWhat You Can Do About It\n\nBecause Lp(a) itself is largely fixed, the practical strategy is to drive every other modifiable risk factor as low as possible — what cardiologists call \"intensifying global risk reduction.\" That means:\n\n- Aggressive LDL lowering. Statins do not lower Lp(a) (they may raise it slightly), but every mg/dL of LDL you remove reduces the total atherogenic particle burden. ApoB-targeted therapies — ezetimibe and PCSK9 inhibitors — are appropriate when LDL targets are missed\n- Tight blood pressure control — Lp(a) damage compounds with hypertension\n- Don't smoke — tobacco multiplies Lp(a)-driven plaque progression\n- Mediterranean-style diet — protective even though it doesn't lower Lp(a) per se\n- Regular aerobic exercise\n- Address inflammation — see our omega-3 page and natural anti-inflammatories page for context\n\nThings That Move Lp(a) — and What They Don't Tell You\n\nSeveral interventions modestly lower Lp(a), but most have failed to translate into better cardiovascular outcomes when tested in trials:\n\n- Niacin (vitamin B3): Extended-release niacin lowers Lp(a) by about 20–25%, but the AIM-HIGH and HPS2-THRIVE trials showed niacin added to statin therapy does not reduce cardiovascular events and increases side effects. [7] Niacin is no longer recommended for Lp(a) reduction\n- PCSK9 inhibitors (evolocumab, alirocumab): Lower Lp(a) by 20–30% as a side effect of LDL reduction. The LDL-lowering itself drives most of the cardiovascular benefit\n- Estrogen lowers Lp(a) but is not used for this indication\n- Aspirin: Some evidence suggests aspirin may particularly benefit people with elevated Lp(a) by reducing the clotting tendency, though this is being formally tested\n\nCounterintuitively, a very low-saturated-fat, high-carbohydrate diet can raise Lp(a) by roughly 10–20%. [8] This doesn't mean you should eat butter to lower Lp(a) — but it does mean blanket \"low-fat\" advice may be the wrong frame for people with high Lp(a), and a Mediterranean pattern (with olive oil, nuts, fatty fish) is generally a better fit. See our Mediterranean diet page for more.\n\nWhat's Coming: RNA-Targeted Therapies\n\nThe biggest shift in Lp(a) management is the arrival of drugs that specifically silence Lp(a) production at the genetic level. Pelacarsen (an antisense oligonucleotide) and olpasiran/lepodisiran/zerlasiran (small interfering RNAs) lower Lp(a) by 70–98% in early trials. [4] The phase 3 outcome trial for pelacarsen (HORIZON) is testing whether reducing Lp(a) actually prevents heart attacks and strokes — results are expected in 2026–2027. If positive, these drugs will likely become standard care for high-Lp(a) patients with established cardiovascular disease.\n\nSee our blood pressure page, homocysteine page, and TMAO page for related cardiovascular biomarkers.","deepText":"Evidence Review\n\nThe case that Lp(a) is a causal — not merely associated — risk factor for cardiovascular disease has been built from three lines of evidence: large prospective epidemiology, Mendelian randomisation, and now early therapeutic trials.\n\nThe strongest epidemiological evidence comes from the Emerging Risk Factors Collaboration meta-analysis by Erqou and colleagues. Pooling individual records from 36 prospective studies including 126,634 participants and 1.3 million person-years of follow-up, the collaboration documented 22,076 vascular and non-vascular outcomes. After adjustment for age, sex, and conventional risk factors, the hazard ratio per one standard deviation higher log-Lp(a) was 1.13 (95% CI 1.09–1.18) for coronary heart disease and 1.10 (95% CI 1.02–1.18) for ischaemic stroke. The associations were continuous, modest at the level of individual standard deviations, but substantial at the upper extreme of the distribution where Lp(a) levels can be 10- to 100-fold above the population mean. Crucially, the relationship was specific: there was no association with non-vascular mortality, indicating Lp(a) was not just a marker of generalised ill health. [2]\n\nThe Mendelian randomisation evidence by Kamstrup and colleagues used the LPA gene's natural genetic variation as an unbiased instrument. The kringle IV type 2 (KIV-2) repeat polymorphism within LPA inversely determines Lp(a) concentration: fewer repeats produce smaller apo(a) isoforms, faster hepatic secretion, and higher plasma Lp(a). Because KIV-2 alleles are randomly assigned at conception (independent of lifestyle confounders), differences in Lp(a) by KIV-2 genotype reflect lifelong differences attributable to Lp(a) itself. The study drew on three Copenhagen studies of white individuals: the Copenhagen City Heart Study (8,637 participants), the Copenhagen General Population Study (29,388 participants) and the Copenhagen Ischemic Heart Disease Study (2,461 participants). In the City Heart Study, observational analysis showed a multivariable-adjusted hazard ratio of 2.6 for myocardial infarction at Lp(a) levels above the 95th percentile compared with levels below the 22nd percentile. Genetically elevated Lp(a), using the KIV-2 instrument, was associated with a hazard ratio of 1.22 (95% CI 1.09–1.37) per doubling of Lp(a) on instrumental variable analysis, against 1.08 (95% CI 1.03–1.12) for plasma Lp(a) levels on Cox regression. [3] The authors concluded that these data are consistent with a causal association between elevated Lp(a) and myocardial infarction — that is, Lp(a) appears to be a causal driver of myocardial infarction, not merely a passive marker.\n\nThe valvular evidence comes from two complementary studies. Thanassoulis and colleagues conducted a genome-wide association study in 6,942 participants from the CHARGE consortium for aortic-valve calcification by CT scan, with replication in 28,193 participants for incident clinical aortic stenosis. The single SNP rs10455872 in LPA — which raises Lp(a) about 4-fold — showed an odds ratio of 2.05 (per allele) for valve calcification across white, African-American, and Hispanic-American participants, with a hazard ratio of 1.68 for incident aortic stenosis in Swedish prospective follow-up, replicated independently in Danish data. [5] Kamstrup and colleagues then quantified the dose-response in 77,680 Copenhagen general-population participants: relative to Lp(a) <20 mg/dL, hazard ratios for incident aortic stenosis were 1.6 at 20–64 mg/dL, 2.0 at 65–90 mg/dL, and 3.0 at >90 mg/dL, with corresponding odds ratios from Mendelian-randomisation analyses showing genetic concordance. [6] These two studies established Lp(a) as the first identified causal driver of calcific aortic valve disease, transforming aortic stenosis from a \"wear and tear\" condition into a partly genetic, partly modifiable disease in development.\n\nThe niacin meta-analysis by Sahebkar and colleagues addressed the historical hope that B3 might be the answer. Pooling 14 randomised placebo-controlled trials with 9,013 participants (5,362 randomised to extended-release niacin), the meta-analysis demonstrated a weighted mean Lp(a) reduction of 22.9% (95% CI −27.3 to −18.5, p<0.001). [7] The Lp(a)-lowering effect is real and reproducible. However, the major outcomes trials AIM-HIGH (n=3,414) and HPS2-THRIVE (n=25,673) tested niacin added to statin therapy in patients with established cardiovascular disease and showed no reduction in cardiovascular events, while increasing rates of bleeding, infection, and new-onset diabetes. The disconnect between Lp(a) lowering and event reduction is most likely because niacin's effect is partial, statin background already optimised LDL, and niacin's other off-target effects offset the benefit. The clinical conclusion is that niacin should not be used to reduce cardiovascular risk via Lp(a) lowering.\n\nThe diet evidence by Faghihnia and colleagues is small but mechanistically important. In a tightly controlled crossover feeding trial of 63 healthy adults, four weeks on a low-fat (20% fat, 5% saturated) high-carbohydrate diet raised mean Lp(a) by approximately 12% relative to a high-fat (40% fat, 13% saturated) diet, while concurrently lowering LDL cholesterol and increasing oxidised-phospholipid burden on apoB lipoproteins. [8] The signal has been replicated in subsequent feeding trials including the GET-READI study in African Americans. The clinical implication is not to recommend high saturated-fat intake — outcomes data still favour Mediterranean and DASH-style patterns — but rather that strict low-fat dieting in someone with already-elevated Lp(a) may worsen one risk axis while improving another, and that \"low fat\" should not be the default lifestyle prescription for high-Lp(a) patients. …","deepTruncated":true,"references":[{"id":"1","title":"A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies","authors":"Tsimikas S","year":2017,"journal":"Journal of the American College of Cardiology","pmid":"28183512","url":"https://pubmed.ncbi.nlm.nih.gov/28183512/"},{"id":"2","title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","authors":"Erqou S, Kaptoge S, Perry PL, Di Angelantonio E, Thompson A, White IR, Marcovina SM, Collins R, Thompson SG, Danesh J","year":2009,"journal":"JAMA","pmid":"19622820","url":"https://pubmed.ncbi.nlm.nih.gov/19622820/"},{"id":"3","title":"Genetically elevated lipoprotein(a) and increased risk of myocardial infarction","authors":"Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG","year":2009,"journal":"JAMA","pmid":"19509380","url":"https://pubmed.ncbi.nlm.nih.gov/19509380/"},{"id":"4","title":"Lipoprotein(a) Reduction in Persons with Cardiovascular Disease","authors":"Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, Tardif JC, Baum SJ, Steinhagen-Thiessen E, Shapiro MD, Stroes ES, Moriarty PM, Nordestgaard BG, Xia S, Guerriero J, Viney NJ, O'Dea L, Witztum JL","year":2020,"journal":"New England Journal of Medicine","pmid":"31893580","url":"https://pubmed.ncbi.nlm.nih.gov/31893580/"},{"id":"5","title":"Genetic associations with valvular calcification and aortic stenosis","authors":"Thanassoulis G, Campbell CY, Owens DS, Smith JG, Smith AV, Peloso GM, Kerr KF, Pechlivanis S, Budoff MJ, Harris TB, Malhotra R, O'Brien KD, Kamstrup PR, Nordestgaard BG, Tybjaerg-Hansen A, Allison MA, Aspelund T, Criqui MH, Heckbert SR, Hwang SJ, Liu Y, Sjogren M, van der Pals J, Kalsch H, Muhleisen TW, Nothen MM, Cupples LA, Caslake M, Di Angelantonio E, Danesh J, Rotter JI, Sigurdsson S, Wong Q, Erbel R, Kathiresan S, Melander O, Gudnason V, O'Donnell CJ, Post WS","year":2013,"journal":"New England Journal of Medicine","pmid":"23388002","url":"https://pubmed.ncbi.nlm.nih.gov/23388002/"},{"id":"6","title":"Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population","authors":"Kamstrup PR, Tybjaerg-Hansen A, Nordestgaard BG","year":2014,"journal":"Journal of the American College of Cardiology","pmid":"24161338","url":"https://pubmed.ncbi.nlm.nih.gov/24161338/"},{"id":"7","title":"Effect of extended-release niacin on plasma lipoprotein(a) levels: A systematic review and meta-analysis of randomized placebo-controlled trials","authors":"Sahebkar A, Reiner Z, Simental-Mendia LE, Ferretti G, Cicero AF","year":2016,"journal":"Metabolism: Clinical and Experimental","pmid":"27733255","url":"https://pubmed.ncbi.nlm.nih.gov/27733255/"},{"id":"8","title":"Changes in lipoprotein(a), oxidized phospholipids, and LDL subclasses with a low-fat high-carbohydrate diet","authors":"Faghihnia N, Tsimikas S, Miller ER, Witztum JL, Krauss RM","year":2010,"journal":"Journal of Lipid Research","pmid":"20713651","url":"https://pubmed.ncbi.nlm.nih.gov/20713651/"}],"wordCount":2005,"source":{"path":"src/content/topics/lipoprotein-a/cardiovascular-risk.md"},"citeAs":"“Does high lipoprotein(a) raise heart attack risk, and should I get tested?.” What's Healthy and Why. https://whatshealthyandwhy.com/lipoprotein-a/cardiovascular-risk","notice":"General information backed by peer-reviewed research, not medical advice."}